Diet plan with resmetirom for fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding a special diet plan to the medication resmetirom helps people with a type of fatty liver disease called MASH. If you have this liver condition (without cirrhosis) and are already starting resmetirom, the diet may improve your liver health and overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with MASH and have moderate liver scarring (fibrosis stage F2 or F3).
- You are just starting resmetirom as part of your regular care.
- You live in one of the five boroughs of New York City.
- You do not have cirrhosis (advanced liver scarring), other liver diseases, or other serious health problems like heart, lung, or kidney failure.
- You are not pregnant or breastfeeding, and you do not drink excessive alcohol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.